Joint repair encompasses cartilage restoration, synovial membrane healing, subchondral bone support, and reduction of the inflammatory environment that prevents endogenous repair. Joints have notoriously poor healing capacity due to limited vascularity in cartilage — making peptide-driven angiogenesis and growth factor support particularly valuable.
1. BPC-157 — Synovial / Cartilage Anti-Inflammatory
BPC-157 promotes angiogenesis in periarticular tissue, reduces synovial inflammation, and has demonstrated regenerative effects on joint cartilage in animal models of osteoarthritis. It downregulates the NF-κB-driven cytokines (IL-1β, TNF-α) that drive cartilage matrix degradation and prevent repair cell migration into avascular cartilage zones.
Dosing Protocol: 250–500 mcg SubQ daily, injected as close to the joint as practical. Cycle: 6–8 weeks; extend to 12 weeks for severe degeneration.
2. TB-500 — Connective Tissue Repair / Flexibility
TB-500 promotes repair of the periarticular connective tissue — capsule, ligaments, menisci — that provides joint stability and protects cartilage from impact loading. It reduces inflammatory adhesions that limit range of motion and supports the fibroblast activity needed to restore joint capsule integrity.
Dosing Protocol: 2 mg SubQ twice weekly for 4–6 weeks, then 2 mg weekly. Stack with BPC-157 for comprehensive joint coverage.
3. GHK-Cu — Cartilage Matrix Synthesis
GHK-Cu stimulates collagen type II synthesis — the primary collagen of articular cartilage — and activates chondrocyte anabolic activity. It also inhibits the MMP-driven matrix degradation that occurs in inflamed joints, providing a dual protective and regenerative effect on cartilage.
Dosing Protocol: 1–2 mg SubQ daily. Can be injected intra-articularly in clinical settings. Topical over the joint as adjunct. Cycle: 8–12 weeks.
4. IGF-1 LR3 — Chondrocyte Proliferation
IGF-1 is the primary anabolic growth factor for chondrocytes — the cells that synthesize and maintain articular cartilage. IGF-1 LR3 directly stimulates chondrocyte proliferation, proteoglycan synthesis, and resistance to apoptosis, providing the cellular anabolic drive needed for cartilage regeneration.
Dosing Protocol: 20–40 mcg SubQ daily. Cycle: 4 weeks on, 4–6 weeks off.
BPC-157 and TB-500 address the inflammatory environment and connective tissue scaffolding surrounding the joint. GHK-Cu drives chondrocyte collagen synthesis within the cartilage itself. IGF-1 LR3 provides the potent anabolic growth factor signal that chondrocytes need to proliferate and rebuild the cartilage matrix — completing a comprehensive joint regeneration protocol.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).